Kinfo
Immunovant Inc. logo

Immunovant Inc.

IMVTNASDAQHealthcare·US · USD
$33.27
-0.35 (-1.06%)
Prices as of October 5, 2026 · market closed

Price

Key statistics

Valuation
Market cap6.94B USD
Enterprise value6.15B USD
Trailing P/E-12.01
Forward P/E-12.22
PEG ratio-2.13
Price / sales0.00
Price / book9.43
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-46.73%
Return on equity-80.10%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA-565.61M USD
Net income-538.22M USD
Diluted EPS-$2.81
Rev. growth (YoY)0.00%
Balance sheet
Total cash797.80M USD
Total debt0.00 USD
Debt / equity0.00
Current ratio7.27
Book value / share$3.57
Cash flow (TTM)
Operating cash flow-414.30M USD
Levered free cash flow-238.70M USD
Shares & price
Shares outstanding206.26M
Float91.79M
Held by institutions53.95%
Beta0.81
50-day MA$39.17
200-day MA$31.74
52-week high$45.42
52-week low$15.95
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-08-06-0.61-0.68−11.48%2026-05-20-0.63-0.67−6.35%2026-02-06-0.69-0.54+21.74%2025-11-10-0.73-0.65+10.96%2025-10-130.020.03+50.00%
About Immunovant Inc.

Immunovant Inc. is a clinical-stage immunology company focused on developing targeted therapies for autoimmune diseases. The company’s current work centers on antibody-based treatments that inhibit the neonatal Fc receptor, a mechanism designed to lower harmful IgG autoantibodies involved in multiple immune-mediated conditions. Its pipeline includes investigational programs such as IMVT-1402 and batoclimab, which are being studied across diseases including myasthenia gravis, thyroid eye disease, Graves’ disease, chronic inflammatory demyelinating polyneuropathy, rheumatoid arthritis, and related autoimmune disorders. Immunovant Inc. operates within the biopharmaceutical sector and is positioned as a specialist in FcRn-based immunology research, with an emphasis on advancing therapies that address the complex biology of autoimmune disease.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Eric Venker M.D., Pharm.D.
Employees
315
Headquarters
Durham, NC, United States

Frequently asked questions about Immunovant Inc.